PURPOSE: Perineural invasion (PNI) in oral squamous cell carcinoma (SCC) is an independent predictor of poor prognosis. As PNI is not always identified with routine histology, a surrogate marker of PNI would improve detection and better inform treatment planning. The chemokines fractalkine (CX3CL1) and its receptor (CX3CR1) have shown such potential in other cancers, but have yet to be investigated with respect to PNI in oral SCC. METHODS: Thirty SCCs of the tongue in which PNI was identified histologically, and 30 in which it was not, were stained for fractalkine and fractalkine receptor using polyclonal antibodies and an immunoperoxidase technique. Tumours were assessed as either positive or negative; no attempt was made to subjectively assess staining intensity or extent. RESULTS: Both markers labelled myofibroblasts in the stroma surrounding the tumour, various neural components, leucocytes, endothelium and salivary myoepithelial cells. Fractalkine also labelled salivary ductal epithelium, vascular smooth muscle and 12/30 SCC which showed PNI. Eight of 30 positive SCCs in which PNI was not identified were also positive for this marker. There was no statistically significant association between fractalkine staining and PNI (p = 0.273). No SCC was positive for fractalkine receptor, but immune dendritic cells within tumour islands were strongly positive, as was striated muscle. CONCLUSIONS: Neither fractalkine nor fractalkine receptor is a reliable surrogate marker of PNI in lingual SCC.
PURPOSE: Perineural invasion (PNI) in oral squamous cell carcinoma (SCC) is an independent predictor of poor prognosis. As PNI is not always identified with routine histology, a surrogate marker of PNI would improve detection and better inform treatment planning. The chemokines fractalkine (CX3CL1) and its receptor (CX3CR1) have shown such potential in other cancers, but have yet to be investigated with respect to PNI in oral SCC. METHODS: Thirty SCCs of the tongue in which PNI was identified histologically, and 30 in which it was not, were stained for fractalkine and fractalkine receptor using polyclonal antibodies and an immunoperoxidase technique. Tumours were assessed as either positive or negative; no attempt was made to subjectively assess staining intensity or extent. RESULTS: Both markers labelled myofibroblasts in the stroma surrounding the tumour, various neural components, leucocytes, endothelium and salivary myoepithelial cells. Fractalkine also labelled salivary ductal epithelium, vascular smooth muscle and 12/30 SCC which showed PNI. Eight of 30 positive SCCs in which PNI was not identified were also positive for this marker. There was no statistically significant association between fractalkine staining and PNI (p = 0.273). No SCC was positive for fractalkine receptor, but immune dendritic cells within tumour islands were strongly positive, as was striated muscle. CONCLUSIONS: Neither fractalkine nor fractalkine receptor is a reliable surrogate marker of PNI in lingual SCC.
Authors: C J Flynn; N Khaouam; S Gardner; K Higgins; D Enepekides; J Balogh; R MacKenzie; S Singh; J Davidson; I Poon Journal: Clin Oncol (R Coll Radiol) Date: 2010-07-21 Impact factor: 4.126
Authors: Federica Marchesi; Lorenzo Piemonti; Giuseppe Fedele; Annarita Destro; Massimo Roncalli; Luca Albarello; Claudio Doglioni; Achille Anselmo; Andrea Doni; Paolo Bianchi; Luigi Laghi; Alberto Malesci; Luigi Cervo; Marialuisa Malosio; Michele Reni; Alessandro Zerbi; Valerio Di Carlo; Alberto Mantovani; Paola Allavena Journal: Cancer Res Date: 2008-11-01 Impact factor: 12.701
Authors: Sylvie Deborde; Tatiana Omelchenko; Anna Lyubchik; Yi Zhou; Shizhi He; William F McNamara; Natalya Chernichenko; Sei-Young Lee; Fernando Barajas; Chun-Hao Chen; Richard L Bakst; Efsevia Vakiani; Shuangba He; Alan Hall; Richard J Wong Journal: J Clin Invest Date: 2016-03-21 Impact factor: 14.808